GeoVax Labs, Inc., a clinical-stage biotechnology company, is set to present groundbreaking data at the Keystone Symposia on Vaccinology in Washington DC. The presentations will focus on the company's GEO-CM04S1 vaccine candidate and its multi-antigen vaccine technology, demonstrating their effectiveness against a range of SARS-CoV-2 variants from Alpha to Omicron. This development is significant as it addresses the challenge of evolving virus strains and the need for vaccines that can provide broad-spectrum immunity.
The first presentation, led by GeoVax scientist Pratima Kumari, PhD, will detail how MVA-vectored multi-antigen COVID-19 vaccines induce protective immunity against various SARS-CoV-2 variants in preclinical models. The second, by Georgia State University scientist Amany Elsharkawy, PhD, will highlight the GEO-CM04S1 vaccine's cross-reactivity against the original SARS-CoV-2 B.1 and Omicron subvariant XBB.1.5. These findings are crucial for developing next-generation vaccines that can protect immunocompromised populations and others for whom current vaccines are less effective.
Mark Newman, PhD, GeoVax's Chief Scientific Officer, emphasized the importance of inducing broadly specific immune responses, particularly T-cell responses to both Spike and Nucleocapsid viral proteins. This approach could revolutionize how vaccines are developed for populations with specific health vulnerabilities. GeoVax's participation in the Keystone Symposia underscores its leadership in leveraging advanced technologies to combat infectious diseases and enhance global preparedness against emerging variants.
